intrODuctiOn T-cell activation plays an important role in cellular and humoral immune response. Activation of naïve T cell is a two-step process, primary signal is provided by antigenic peptide presented by major histocompatibility complex to T-cell receptor and secondary signal is provided by co-signalling molecules. Co-signalling molecules are co-stimulatory and co-inhibitory molecules (receptors) on T-cell surface. T-cell enters into anergy if secondary signal by co-stimulatory molecule is absent. [1] CD28 and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) are co-stimulatory and co-inhibitory molecules, respectively. Both molecules have high degree of sequence similarity but function differently. [2] CTLA 4 is a gene located on human chromosome 2q33 acting as negative regulator of immune response, i.e., suppressing T-cell proliferation, whereas two genes CD28 and inducible co-stimulator act as positive regulator of immune response. [3] CD28 and CTLA-4 bind to B7.1 and B7.2. CTLA-4 is having two splice variants due to alternative splicing, one is membrane-bound CTLA-4 having Background: Cervical cancer (CaCx) is the second most common cancer in Indian women. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) + 49 AA polymorphism is known to be associated with CaCx. Current attempt is to use immunotherapy for the treatment of metastatic melanoma and metastatic castration-resistant prostate cancer, i.e., blocking of CTLA-4 using a fully human monoclonal CTLA-4 antibody to disrupt its inhibitory signal. This allows the CTLs to destroy the cancer cells. There is no information available on the soluble level of CTLA-4 on which the immunotherapy is targeted. This is specifically in Indian population including cases with CaCx. Objective: The aim of this study is to evaluate the levels of soluble CTLA-4 (sCTLA-4) in human papillomavirus (HPV)-infected women with or without CaCx and their association with the polymorphism at CTLA-4 + 49 A/G and CTLA-4 −318 C/T genotypes. Materials and Methods: This is an exploratory case-control study involving two groups of HPV-infected women, the cases were with invasive CaCx and the control group was women with the healthy cervix. sCTLA-4 levels were measured using ELISA in 92 CaCx cases and 57 HPV-positive women with the healthy cervix. Results: Both cases and controls have similar sCTLA-4 levels. Comparison of CTLA-4 + 49A/G and −318 C/T genotypes with sCTLA-4 levels among cases and control also did not show any statistically significant difference. Conclusion: The present study suggests sCTLA-4 levels are not affected by a polymorphism at + 49 A>G CTLA-4. Hence, levels of CTLA-4 are similar in both CaCx cases and control group.
Polymorphisms in Cytotoxic T-lymphocyte Associated Antigen 4 Gene Does Not Affect sCytotoxic T-lymphocyte Associated Antigen 4 Levels in Human Papillomavirus-Infected Women
with or without Cervical Cancer 4 exons: exon 1 encodes for leader peptide, exon 2 encodes ligand binding domain, exon 3 for transmembrane and exon 4 is cytoplasmic domain. The splice variant of CTLA-4 formed due to alternative splicing lacks exon 3, a transmembrane spanning domain and forms the soluble CTLA4 (sCTLA-4). According to one report exon 2 of CTLA-4 codes for transmembrane region is deleted in alternative splicing and extra 22 amino acids are added before translation termination. [4] [5] [6] Splice variant of CTLA-4 (sCTLA-4) and full-length CTLA-4 (flCTLA-4) both have same amino acids (MYPPPY motif) in the critical B7 binding region, and hence, sCTLA-4 have same binding capacity to B7 as that with flCTLA-4. [4, 7] Previous studies have revealed significant association of polymorphisms in CTLA-4 gene at + 49 A/G (rs231775) and susceptibility to multiple types of cancer such as breast cancer, lung cancer, oesophageal cancer, gastric cancer, colorectal cancer, renal cell cancer, oral cancer and cervical cancer (CaCx). [8] [9] [10] [11] [12] [13] [14] [15] [16] There are reports showing sCTLA-4 interferes with binding of CD28/B7, thus affecting T-cell proliferation. [17] Blockade of CTLA-4 using anti CTLA-4 antibodies increased T-cell proliferation and there are reports showing in vivo administration of antibody against CTLA-4 resulted in rejection of tumours. [18] [19] [20] This blocking activities are made by use of "Ipilimumab," which is a fully human monoclonal antibody that binds to the inhibitory CTLA-4, thereby enhancing antitumour immunity. [21] Responses triggered by ipilimumab are not believed to be antigen-specific, and instead result from prevention of the CTLA-4-mediated downregulation of T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the CTLs to destroy the cancer cells. This beneficial role of Ipilimumab is seen in patients with advanced melanoma for which, ipilimumab has been approved in more than 40 countries. [22] Although there was no significant difference between the ipilimumab group and the placebo group regarding overall survival, some evidence of antitumour activity was reported with ipilimumab treatment in a population with advanced metastatic castration-resistant prostate cancer. [21] Polymorphism in CTLA-4 gene is known to be associated with CaCx. [13] [14] [15] [16] CaCx is the second most common cancer in women. In India, the current estimates indicate approximately 132,000 new cases and 74,000 deaths annually, accounting for nearly 1/3 rd of the global CaCx deaths. Hence, there is a need to evaluate polymorphism at CTLA-4 + 49 A/G and CTLA-4 −318 C/T genotypes and their association with the levels of sCTLA-4. This may help in documenting evidence for use of anti CTLA-4 antibodies to block CTLA-4 to disrupt its inhibitory signal. The present study was undertaken to evaluate the sCTLA-4 levels in established CaCx cases with or without CTLA-4 + 49 amyloid A (AA), −318 C/T polymorphism in an attempt to gather information if in future blocking of CTLA-4 will be beneficial for CaCx cases.
matErials anD mEtHODs

Study subjects
This was an exploratory case-control study involving two groups of patients. The first group was patients with invasive following hybridization with HPV type-specific probes. [23] Women with abnormal Papanicolaou test and any other RTI or STI were excluded from the study. This study was approved by institutional and respective Hospital Ethics Committees.
Cytotoxic T-lymphocyte-associated antigen 4 genotyping
CTLA-4 + 49 A/G and CTLA-4 −318 C/T genotypes results are used from the earlier study [16] to correlate the single nucleotide polymorphism (SNP) with the sCTLA-4 levels in the serum of the same individuals.
Serum soluble cytotoxic T-lymphocyte-associated antigen 4 levels
Serum was preserved from blood collected in plain vacutainer from patients enrolled from both TMH and KEM Hospital which was used to detect sCTLA-4 levels. sCTLA-4 level was measured using Human CTLA-4 ELISA kit (Qayee-Bio for life sciences, China).
Statistical analysis
The Mann-Whitney and Kruskal-Wallis was used for comparison of the distribution of observed genotypes for CTLA-4 + 49 A/G and −318 C/T polymorphisms with levels of sCTLA-4 in CaCx.
rEsults
In the study, there were 92 cases with invasive CaCx (median age: 48 years) and 57 HPV-infected women (median age: 38 years) with normal cytology. None of the women in any of the groups had any family history of cancer. Cases and controls were ethnically matched.
HPV was detected in all the biopsy tissues, collected from the 92 enrolled women with CaCx. The overall infection rate of HPV type 16 and type 16 + 18 in CaCx cases was found to be 79.38% and 41.23%, respectively. In control, HPV infection rate was 7.92% (57 of 720). HPV typing was done in 42 specimens out of 57 women. The distribution of HPV 16 and 18 was 19.05% and 11.9%, respectively. In 15 specimens, typing could not be done due to insufficient DNA.
Circulating sCTLA-4 levels were measured in serum of these cases and controls. Serum levels of cases are comparable with that of controls. Earlier study results revealed that CTLA-4 + 49AA genotype (33.7% vs. 12.3%, P = 0.009) frequency was significantly high in study group as compared to control group. The G/G genotype frequency (35.1% vs. 25.0%, P = 0.04) was significantly higher in HPV-positive women without any cervical abnormality compared to HPV-infected women with CaCx. The frequency of −318 C/C, C/T in the study population (n = 149) was found to be 98.0% and 2.0%, respectively. The C/C genotype (97.8% vs. 98.2%) frequency in both cases and control was similar.
Comparison of CTLA-4 + 49A/G and −318 C/T genotypes with sCTLA-4 levels among cases and control did not show any statistically significant difference [ Table 1 ].
DiscussiOn
Alternative splice variant of CTLA-4 which lacks transmembrane region is sCTLA-4 (sCTLA-4). In the present study, no statistically significant association was found in the levels of sCTLA-4 when compared between CaCx cases and controls in CTLA-4 + 49 A/G (2.85 ± 0.78ug/L versus 2.87 ± 0.87ug/L, P = 0.98) and in CTLA-4 −318 C/T (2.86 ± 0.75 ug/L versus 2.87 ± 0.877ug/L, P = 0.98), similar to that of study in autoimmune diseases. [16] This is in contrast to the findings observed in breast cancer cases where significantly higher sCTLA-4 levels were found in cases as compared to that of control population (23.5 ± 14.96 ng/ml vs. 7.69 ± 4.04 ng/ml, P < 0.001). [17] In our study, both cases and controls have similar sCTLA-4 levels. The level of sCTLA-4 is similar to that observed among the control cases of Iran, a different ethnic population. In earlier study we did not find any difference between the groups at the promoter region of CTLA-4 gene −318 C/T variant, however, we found a significant association of CTLA-4 49 AA with CaCx. [16] Hence, we wanted to see if there is also a change in sCTLA-4 levels between the CaCx cases and HPV-infected women with normal cervix. However, there is no change in the corresponding levels of sCTLA-4, similar to another study carried out among the cases with autoimmune diseases including Type-1 diabetes, which suggested no association of CT-60 SNP, another SNP present in CTLA-4 gene, with the expression of sCTLA-4. [24] CTLA-4 protein is immunosuppressive in nature and many polymorphisms in its gene are known to have an effect on its immunosuppressive activity. The + 49 G/A polymorphism is the most commonly studied SNP in CTLA-4 gene. CTLA-4 + 49 A>G SNP, both 49AA and 49AG genotypes are significantly associated with risk of multiple types of cancer, including CaCx as seen in our earlier study. [16] Results from stratified analysis by ethnic subgroups are also consistent. The variant A allele is less frequent in Asians (32%) than in Caucasians (62%), but the genetic effect conferred by the A allele seems consistent in different ethnic populations. The regulation of CTLA-4 expression is pivotal as its concentration on the cell membrane determines the strength of down-regulatory signals for T cells. Thus, maintenance of an optimal surface expression level of CTLA-4 seems to be crucial for the regulation of T-cell responses and peripheral tolerance, and for preventing autoimmunity. Since CTLA-4 down-regulates T-cell production in individuals with GG genotype (less CTLA-4 production) has higher T-cell proliferation than those with the AA genotype. [16, 25] It is due to this reason that the risk allele for susceptibility to cancer (allele A) is the opposite of that found for susceptibility to autoimmune diseases (allele G). [26] As CTLA-4 synthesis depends on the rate of gene transcription and/or translation, polymorphisms in the corresponding genes might result in abnormal expression and function, as well as dysregulated trafficking of CTLA-4 within cellular compartments. [26] CTLA-4 is a negative regulator of immune response, hence prompted efforts to develop cancer immunotherapy targeting this signalling molecule to enhance tumour regression. [27] Inhibition of CTLA-4 activity with anti-CTLA-4 antibody allows T-cell expansion to continue after vaccination with tumour antigen. To identify genetic factors that might affect response to and toxicity of CTLA-4 antibody therapy, several CTLA-4 polymorphisms have been investigated. [21, 22] Patients with metastatic melanoma having the 49A allele showed better response to anti-CTLA-4 therapy than those having the 49G allele, which seems to be logical because the CTLA-4 49 A allele is correlated to enhanced inhibition of T-cell proliferation and activation. In addition, the significant rate of immune-related adverse events and other adverse events compels the development and prospective validation of a predictive biomarker that would allow pretreatment selection of patients likely to benefit from treatment. One of them could be CTLA-4 genotype-haplotype as genetic marker for personalised anti-CTLA-4 therapy. Once this genetic makeup is established, additional option is to establish the correlation between SNPs and T-cell immune proliferation, which is time consuming, depends on availability of culture facility and also not cost effective for the patients. However, our study did not reveal any association between polymorphism in CTLA-4 genes and the levels of sCTLA-4, specifically in individuals with invasive CaCx, though our study limited to only 2 SNPs. Hence, further analysis to correlate the stage of the diseases with immune proliferation and measurement of sCTLA-4 levels may not contribute in CaCx management.
cOnclusiOn
The present study suggests sCTLA-4 levels are not affected by polymorphism at + 49 A>G CTLA-4. Hence, levels of CTLA-4 are similar in both CaCx cases and control group.
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